All News
The 2025 Rheumatology Year in Review
The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines and practices that will impact patient care for rheumatic diseases.
Read ArticleAntirheumatic drug use with rheumatoid arthritis pregnancies
A nationwide Norwegian registry study of rheumatoid arthritis (RA) pregnancies showed that while medication use increased during pregnancy, many discontinued treatment during pregnancy, only to resumed it after childbirth.
Read ArticleRheumatoid & Inflammation Testing
Master the dos and don'ts of ordering RF, CCP (ACPA), and inflammatory markers that could transform your diagnostic accuracy.
Read Article
FIBROSCANS in 60 RA pts on #MTX for 5 yrs w/ liver studies. Mean age = 39.5yrs, w/ Dz Dur 8.2 yrs, mean BMI 24.4 & MTX 12.5–25 mg for ~8 yrs (cum dose 6728mg). All had normal AST, ALT, APRI, Abd US; fibroscan score = 170 ((steatosis grade 0). Only 4(6.7 %) had mild, fibrosis https://t.co/7SACsEYi37
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid & Inflammation Testing
https://t.co/tEkJWGp7DK https://t.co/ZO4BV2mmhn
Links:
Dr. John Cush RheumNow ( View Tweet)
Systematic review of cardiovascular death in systemic immune-mediated Dz (SIDs): 39 studies, 171,748 pts - SIDs assoc w/ signif. higher CV mortality (HR 1.26; 1.09-1.47; p = 0.002), especially for RA, SLE, GPA & females. 92% of CV deaths from acute coronary syndrome (ACS) https://t.co/ogLhqKMwON
Dr. John Cush RheumNow ( View Tweet)
101 Meditteranean pregnant RA compared to 236 non-RA controls. HCQ & SSZ (45-73%) most used; biologics less (25%). RA had signif more adverse preg outcomes - LBW (OR 3), C-section (OR 2.55), fewer neonatal deaths (OR 0.38). RA had more miscarriages (20 v 1%) & fewer live births https://t.co/3nTdXEbBHI
Dr. John Cush RheumNow ( View Tweet)
Kick off with a powerhouse RA session! ⚡️
Drs. Elena Myasoedova, Kristen Demoruelle, & Jeffrey Sparks dive deep into: 📉 Mortality Trends 🧬 The Mucosal Hypothesis 🫁 Recent ILD Advances
Ends with a live faculty Q&A. A can’t-miss for RA clinicians in 2026! 🩺
Registration https://t.co/Z9oOkAyWPK
Dr. John Cush RheumNow ( View Tweet)
PNAS/Yale researchers report on a mice model of RA, MIF-dependent, CD74+ memory T cells (normally very few) expand & incr in number in the inflammed joint. When MIF genes were deleted in a CIA model, arthritis was prevented. MIF-dependent, CD74+ T cells promote chronic synovitis. https://t.co/pdPIqtSCwG
Dr. John Cush RheumNow ( View Tweet)
2026 Resolutions (1.9.2026)
Dr. Cush reviews the news, announcements and journal articles from this past week on RheumNow. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!
https://t.co/DgY2trZGKA https://t.co/3ka4SDRnJO
Dr. John Cush RheumNow ( View Tweet)
FIBROSCANS in 60 RA pts on #MTX for 5 yrs w/ liver studies. Mean age = 39.5yrs, w/ Dz Dur 8.2 yrs, mean BMI 24.4 & MTX 12.5–25 mg for ~8 yrs (cum dose 6728mg). All had normal AST, ALT, APRI, Abd US; fibroscan score = 170 ((steatosis grade 0). Only 4(6.7 %) had mild, fibrosis https://t.co/OOctcfI1sT
Dr. John Cush RheumNow ( View Tweet)
DANFLU-2 RCT of 332 438 elderly (43 881 w/ diabetes) tested high (HD-IIV) vs standard dose SD-IIV) flu vaccine. HD-IIV signif. reduced cardioresp., CV, CHF, influenza, hospitalizations vs SD-IIV, irrespective of DM status. Similar results previously seen in a Canadian RA pop. https://t.co/GGZPThoHrs
Dr. John Cush RheumNow ( View Tweet)
UK study of 1846 RA pts starting a b/tsDMARDs, ~30% on steroids & majority (2/3) continued use over the first year of new novel treatment. This suggests these aer either severe RA pts or that we are not vigilant in limiting/weaning/stopping steroids in RA patients - which is it? https://t.co/TrAktincKT
Dr. John Cush RheumNow ( View Tweet)
Japan retrospective study of 38 RA pts who developed MTX assoc lymphoproliferative disorder (LPD) - 22 w/ spontaneous regression (SR) vs 16 non-SR (w/ 5 deaths). non-SR Pt had higher LDH levels at Dx & lower lymphocyte recovery 1 mo. post MTX withdrawal & higher mortality risk https://t.co/TRizVwP2BQ
Dr. John Cush RheumNow ( View Tweet)
Plenty of evidence that toxic environmental exposures increase #RA risk. Full read, intelligent report from Stanhope et al showing how (healthy environmental) green space exposures are protective & capable of preventing RA!! Lifestyle is gigantically important in your https://t.co/LUWmHhUT7F
Dr. John Cush RheumNow ( View Tweet)
VA registry study; among 2771 RA pts (~65y), 64 (2.3%) had CPPD by ICD9/10 codes. RA+CPPD pts signif older [68 v. 64y], w/ more comorbidity/OA (94 v 80%), spine Dz, DM, but less ACPA (63 v 78%). SNRA+CPPD achieved less LDA, more use of pred & b/tsDMARDs (OR >2), death, TJR. Is https://t.co/hUPJzDseVc
Dr. John Cush RheumNow ( View Tweet)
Systematic review of Difficult-to-treat RA (D2T-RA): 23 articles, 27,987 RA pts from 13 countries - pooled prevalence of D2T-RA was 11.7% (10.9% overall; 13.2% in b/tsDMARDs-treated RA). 47% D2T-RA had persistent inflammatory refractory RA (PIRRA). Prevalence decreased w/ https://t.co/0Gatzbfxid
Dr. John Cush RheumNow ( View Tweet)
UK study of 1846 RA pts starting a b/tsDMARDs, ~30% on steroids & majority (2/3) continued use over the first year of new novel treatment. This suggests these aer either severe RA pts or that we are not vigilant in limiting/weaning/stopping steroids in RA patients - which is it? https://t.co/7NWeAWTjSy
Dr. John Cush RheumNow ( View Tweet)
Japan retrospective study of 38 RA pts who developed MTX assoc lymphoproliferative disorder (LPD) - 22 w/ spontaneous regression (SR) vs 16 non-SR (w/ 5 deaths). non-SR Pt had higher LDH levels at Dx & lower lymphocyte recovery 1 mo. post MTX withdrawal & higher mortality risk https://t.co/SsBQRxFvD1
Dr. John Cush RheumNow ( View Tweet)
JAMA teaching case: 57 yoF w/ RA Rx w/ HCQ, NSAID, TNFi (ETN -->ADA) develops a new rash - pruritic vesicles/papular on neck, mouth, ears, chest, hands w/ some becoming ulcerated plaques, ESR >100. WHAT TO DO? A) steroids; B) stop ADA; C) Benadryl or D) Read more? Pt had https://t.co/DQpeUOC5I3
Dr. John Cush RheumNow ( View Tweet)


